You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-5. Characteristics of all clients entering treatment: demographics and primary drug at treatment in 2005 or most recent year available [see all tables in this series...]

Part (vi) Primary drug type used by female clients (percent of all female clients)

Country		Opioids	Cocaine	Amphe tamines	Ecstasy	Halluci nogens	Cannabis	Others	% currently injecting any drug
Bulgaria		92.2	0.8	0.8	0.1	0.0	3.2	2.9	59.7
Czech Republic		23.3	0.2	61.2	0.2	0.2	11.9	3.0	51.2
Denmark		39.6	5.3	7.1	0.9	0.0	26.0	21.1	9.8
Germany	(1)	56.6	5.0	7.0		0.2	19.9	11.3	11.8
Ireland		72.8	7.0	0.7	2.3	0.0	13.3	3.9	23.6
Greece		87.3	2.8	0.0	0.1	0.3	7.3	2.2	33.0
Spain	(2)	50.7	33.8	0.8	0.5	0.1	10.1	4.0	10.9
France		46.0	6.8	0.5	1.2	0.8	37.3	7.4	12.5
Italy	(3)	65.5	14.4	0.4	0.8	0.0	13.6	5.3	19.3
Cyprus		63.2	12.3	0.0	0.0	1.8	19.3	3.4	38.6
Latvia	(4)	34.0	1.1	26.6	1.1	0.0	8.5	28.7	50.5
Lithuania	(1)	81.7	0.2	4.0		0.1	0.2	13.8
Luxembourg		65.0	18.0	1.0	7.0	1.0	8.0	0.0	74.0
Hungary		11.0	1.0	4.0	4.0	1.0	13.0	66.0
Malta		69.0	10.0	0.0	1.0	0.0	14.0	6.0	48.0
Netherlands		26.7	30.3	5.9	2.6	0.1	26.8	7.6	1.6
Austria	(5)	100.0	0.0	0.0	0.0	0.0	0.0	0.0
Poland	(6)	19.5	1.1	7.1		0.4	1.2	70.7
Portugal	(4)	77.8	8.7	0.0	0.0	0.0	9.3	4.2	3.9
Romania		31.9	0.4	0.0	0.7	0.0	1.8	65.3
Slovenia	(2)	88.0	1.9	0.2	0.3	0.0	9.4	0.2	33.8
Slovakia		51.4	0.2	21.6	0.2	0.0	10.4	16.2	51.7
Finland		43.0	0.0	31.0	0.0	0.0	14.0	12.0	51.0
Sweden		28.4	1.1	39.9	0.3	0.2	11.9	18.2	27.6
United Kingdom	(7)	67.3	9.6	4.5	1.0	0.1	11.8	5.6	24.0
Turkey		51.7	4.7	0.7	10.1	0.0	17.4	15.4	28.9

Notes:

Data were not available for: Belgium, Estonia, Norway.

(1) Data on amphetamines include amphetamines and ecstasy.

(2) Last data available refer to 2004.

(3) Until 2004, 'all clients' reported clients continuing in or entering treatment in reported year; 2005 data are conformant with the TDI protocol.

(4) Data by gender refer to first treatments.

(5) Data refer to clients in substitution treatment only; figures for opioids as main drug and injecting use are consequently 100%.

(6) Last data available refer to 2003. Data on amphetamines include amphetamines and ecstasy.

(7) Data relate to the period from 1 April 2004 to 31 March 2005 for UK.

See also 'General notes for interpreting data' on the Explanatory notes and help page.

Sources:

2006 Reitox national reports - Standard table 3. See [Table TDI-1 Part (0)] for details on sources.